Nov 6, 6:47 AM ET
Moderna reported third-quarter 2026 revenue of $1.3 billion and net income of $0.2 billion, returning to a profit compared to a net loss in the same period last year. Driven by this performance and pipeline progress, the company raised its full-year 2026 revenue growth outlook to 15% to 25% and increased its expected year-end cash and investments balance to between $8.1 billion and $8.3 billion. Shareholders also received updates on positive Phase 3 data for intismeran in melanoma and the U.S. FDA approval of the mFLUSIVA vaccine.
- Third-quarter 2026 total revenue grew 29% year-over-year to $1.3 billion, with GAAP net income of $162 million or $0.38 per diluted share.
- Full-year 2026 expected revenue growth was raised to 15% to 25%, up from the previous expectation of up to 10% growth.
- Year-end 2026 cash and investments are now projected to be $8.1 billion to $8.3 billion, bolstered by operational execution and a $2.6 billion net proceeds convertible notes offering.
- Research and development expenses for 2026 are now expected to be approximately $2.7 billion, reduced from the prior estimate of approximately $2.9 billion.
Read the filing on SEC.gov ↗
Sep 30, 7:15 AM ET
Moderna appointed Juan Andres, a former Moderna executive who retired in 2023, as its new Chief Operating Officer, effective October 5, 2026, reporting to CEO Stephane Bancel. The company also said Chief Technical Operations and Quality Officer Jerh Collins will retire, so the appointment adds a senior operations role while a manufacturing leader departs.
- Juan Andres, 62, starts as COO on October 5, 2026 and will serve on the Executive Committee.
- Andres receives an initial base salary of $800,000 and a target annual bonus of 90% of base salary.
- A new hire equity award with total value of $5,000,000 is subject to four-year vesting; annual equity target is $4,000,000 to $5,000,000.
- Jerh Collins, Ph.D., Chief Technical Operations and Quality Officer, will retire; the filing gives no retirement date.
Read the filing on SEC.gov ↗
Sep 1, 4:37 PM ET
Moderna completed a private offering of $3.0 billion in 0.00% convertible senior notes due March 1, 2032, including the full exercise of a $400 million option for additional notes. The notes carry no regular interest, and the company expects about $285.0 million of net proceeds to go toward the cost of capped call transactions, with the rest for general corporate purposes, which may include oncology growth and debt repayment.
- Offering size: $3.0 billion aggregate principal, including $400 million from the initial purchasers' option, completed September 1, 2026
- Initial conversion price of about $210.58 per share, a 47.5% premium over the $142.77 closing price on August 27, 2026
- Capped call transactions cost approximately $285.0 million; estimated net proceeds are about $2,957.3 million including the option
- Notes may not be redeemed before September 6, 2029, except in a cleanup redemption
Read the filing on SEC.gov ↗
Jul 31, 7:03 AM ET
Moderna reported second-quarter 2026 revenue of $145 million, up from $142 million a year earlier, and a GAAP net loss of $(0.8) billion, or $(1.97) per share, versus $(2.13) per share in the prior-year quarter. The company improved its 2026 operating expense outlook, lowering R&D to approximately $2.9 billion and projecting year-end cash and investments of $4.7 to $5.2 billion, but its norovirus candidate mRNA-1403 did not meet early-success criteria at a Phase 3 interim analysis.
- Q2 2026 revenue $145 million vs $142 million; net loss $(782) million vs $(825) million
- Loss per share $(1.97) vs $(2.13) in Q2 2025
- 2026 R&D now approximately $2.9 billion (from $3.0 billion); cost of sales approximately $1.7 billion (from $1.8 billion), including a $0.9 billion litigation settlement charge
- mRNA-1403 norovirus Phase 3 missed interim early-success criteria; mFLUSIVA U.S. PDUFA date is August 5, 2026
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.